GlassScriptPhysician profile
Shauna M Everett
NPI 1386970325
$1,544.63
in general payments reported to CMS, 2019-2025
25 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2023: $37.08 · 2024: $236 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $178.72 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Boston Scientific Corporation | $138.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $128.27 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2025 | |
| Amgen INC. | $124.23 | 2025 | Tavneos |
| Exelixis INC. | $123.37 | 2025 | Cabometyx |
| Pfizer INC. | $87.27 | 2025 | |
| Janssen Biotech, INC. | $85.22 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Alexion Pharmaceuticals, INC. | $62.46 | 2025 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.79 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.86 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $49.93 | 2025 | |
| Irhythm Technologies, INC. | $49.01 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $36.31 | 2024 | |
| Abbvie INC. | $33.54 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Legend Biotech USA INC. | $23.57 | 2025 | Carvykti |
| Medtronic, INC. | $22.00 | 2024 | Corevalve Evolut R |
| Eisai INC. | $21.53 | 2025 | |
| Incyte Corporation | $20.15 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Beone Medicines USA, INC. | $19.75 | 2025 | Brukinsa |
| Astellas Pharma US INC | $18.89 | 2025 | Padcev |
| Sumitomo Pharma America, INC. | $17.92 | 2025 | Orgovyx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.07 | 2023 | Lifevest |
| Mallinckrodt Hospital Products INC. | $14.76 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shauna Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.